Work

Data from Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer

Year: 2023

Type: other

Abstract: In vitro resistance modeling coupled with molecular analysis of autopsy tumor samples from patients with acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in lung cancer reveal novel biological insights into mechanisms of disease progression. These kinds of studies will facilitate the development of rationally targeted therapies in the era of genetically informed cancer medicine. Clin Cancer Res; 16(22); 5371–3. ©2010 AACR.

DOI: 10.1158/1078-0432.c.6519257.v1

Authors: Juliann Chmielecki, William Pao

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361818141

Cites:

Cited by:

Related to: 10